Figure 3.

Blood pressure and heart rate at given time points. Safety analysis set excluding patients with incorrectly assigned doses. Data are displayed as mean ± standard error. (A) systolic blood pressure; (B) diastolic blood pressure; (C) heart rate, difference in heart rate between the placebo and 2.5 mg vericiguat groups at 12 weeks was −3.7 bpm (95% CI −7.32 to 0.00 bpm), and between the 10 mg and placebo groups −5.9 bpm (95% CI −10.0 to −1.9 bpm). Baseline-adjusted linear regression slope −0.34 bpm (95% CI −0.66 to −0.02 bpm). bpm, beats per minute; CI, confidence interval.